C型肝炎病毒感染之細胞生物學、免疫控制及治療__臺灣人文及社會科學引文索引資料庫

:::

詳目顯示

第 1 筆 / 總合 1 筆

/1頁

來源文獻資料
摘要
外文摘要
引文資料

題名：	C型肝炎病毒感染之細胞生物學、免疫控制及治療
書刊名：	弘光學報
作者：	唐蘊慧／簡姿娟／謝東呈
作者(外文)：	Tang, Yun-hui／Chien, Tzu-chuan／Shieh, Dong-chen
出版日期：	2010
卷期：	61
頁次：	頁1-25
主題關鍵詞：	C型肝炎病毒；干擾素α；雷巴威林；Hepatitis C virus；HCV；Interferon-α；Ribavirin
原始連結：	連回原系統網址
相關次數：	被引用次數:期刊(1) 博士論文(0) 專書(0) 專書論文(0) 排除自我引用:1 共同引用:0 點閱:28

C型肝炎病毒 (hepatitis C virus; HCV ) 感染是最常見的輸血性病毒感染，全世界約有三億人口被感染，也是造成肝硬化及肝細胞癌的主因。目前C型肝炎之治療是以干擾素α與Ribavirin為主，但其成功治癒率僅約為50%。因此，更有效及低副作用的新型治療藥物的研發是必需且急迫的。本文探討近來HCV病毒學的進展及瞭解病毒的生命週期和致病機轉以提供研發新型抗病毒製劑的參考。本文亦描述近期HCV流行病學、臨床表現及診斷檢驗的發展。

以文找文

Hepatitis C virus (HCV) infection is the most common chronic blood-borne viral infection affecting about 300 million people worldwide, and is a leading cause of liver cirrhosis and hepatocellular carcinoma. Currently, treatment is restricted to a combination of interferon-α and ribavirin, which leads to a successful outcome of only about 50% of patients. Therefore, new effective treatments with tolerable side-effect profiles are needed urgently. Herein, we review progress in HCV biology with respect to the life-cycle of virus, pathogenesis of infection and development of specific antiviral treatment. We also discuss recent advance in epidemiology, clinical manifestation, and diagnostics of HCV infection.

以文找文

期刊論文
1.	趙玉雯、吳義勇(20020200)。C型肝炎病毒感染于末期腎病接受透析病患及腎臟移植病患之近況趨勢。腎臟與透析，14(1)，19-25。延伸查詢
2.	蔡順隆(20030600)。B型與C型肝炎的免疫致病機轉。當代醫學，30(6)=356，437-448。延伸查詢
3.	Bartenschlager, R.(2006)。Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture。Curr Opin Microbiol，9，416-422。
4.	Eichhorst, S. T.(2005)。Modulation of apoptosis as a target for liver disease。Expert Opin Ther Targets，9，83-99。
5.	Deveraux, Q. L.、Reed, J. C.(1999)。IAP family proteins- suppressors of apoptosis。Genes Dev，13，239-252。
6.	Weber, F.(2007)。Interaction of hepatitis C virus with the type I interferon system。World J Gastroenterol，13(36)，4818-4823。
7.	Gil, J.、Esteban, M.(2000)。Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action。Apoptosis，5，107-114。
8.	Hiscott, J.(2007)。Triggering the innate antiviral response through IRF-3 activation。J Biol Chem，282，15325-15329。
9.	Kubo, M.、Hanada, T.、Yoshimura, A.(2003)。Suppressors of cytokine signaling and immunity。Nat Immunol，4，1169-1176。
10.	Kumar, S.(2007)。Caspase function in programmed cell death。Cell Death Differ，14，32-43。
11.	Levy, D. E.、Darnell, J. E.(2002)。Stats: transcriptional control and biological impact。Nat Rev Mol Cell Biol，3，651-662。
12.	Lindenbach, B. D.、Evans, M. J.、Syder, A. J.(2005)。Complete replication of hepatitis C virus in cell culture。Science，309，623-626。
13.	Meylan, E.、Curran, J.、Hofmann, K.(2005)。Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus。Nature，437，1167-1172。
14.	Samuel, C. E.(2001)。Antiviral actions of interferons。Clin Microbiol Rev，14，778-809。
15.	Schaefer, U.、Voloshanenko, O.、Willen, D.、Walczak, H.(2007)。TRAIL: a multifunctional cytokine。Front Biosci，12，3813-3824。
16.	Shuai, K.、Liu, B.(2005)。Regulation of geneactivation pathway by PIAS proteins in the immune system。Nat Rev Immurol，5，593-605。
17.	許景盛、高嘉宏(20050300)。C型肝炎治療的新進展--干擾素相關治療的影響因素和因應策略。當代醫學，32(3)=377，218-231。延伸查詢
18.	Chen, Chien-hung、Yang, Pei-ming、Huang, Guan-tarn、Lee, Hsuan-shu、Sung, Juei-low、Sheu, Jin-chuan(20070200)。Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants。Journal of the Formosan Medical Association，106(2)，148-155。

其他
1.	莊萬龍、余明隆(2007)。慢性C型肝炎之治療。延伸查詢
2.	曾光毅、曾高智、林佩璇(2004)。現階段C型肝炎的預防與治療。延伸查詢
3.	黃俐綾、謝東呈(2008)。從C型肝炎病毒感染細胞之凋亡談現行治療之免疫機轉。延伸查詢
4.	楊慧美、林柏煌、侯東旭(2008)。雲林縣大埤鄉偏遠地區年滿65歲以上C型肝炎之感染率。延伸查詢
5.	謝佩真、郭行道、卓文春、廖永樑、林靖南(2009)。C型肝炎病毒基因分型及其臨床重要性。延伸查詢
6.	Akuta, N.; Suzuki, F.; Hirakawa, M. et al.(2009)。A matched casecontrolled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response。
7.	Aach, R. D.; Stevens, C. E.; Hollinger, F. B. et al.(1991)。Hepatitis C virus infection in posttransfusion hepatitis。
8.	Asselah, T.; Bieche, I.; Paradis, V.; Bedossa, P.; Vidaud, M.; Marcellin, P.(2007)。Genetics genomics and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C。
9.	Asselah, T.; Rubbia, B. L.; Marcellin, P.; Negro, F.(2006)。Steatosis in chronic hepatitis C: why does it really matter。
10.	Agnello, V.; Rosa, F. G.(2004)。Extrahepatic disease manifestations of HCV infection: some current issues。
11.	Branch, A. D.; Stump, D. D.; Gutierrez, J. A.; Eng, F.; Walewski, K. L.(2005)。The hepatitis C virus alternate reading frame(ARF) and its family of novel products:the alternate reading frame protein/ F-protein the doubleframeshift protein and others。
12.	Buratti, E.; Tisminetzky, S.; Zotti, M.; Baralle, F. E.(1998)。Functional analysis of the interaction between HCV 50’ UTR and putative subunits of eukaryotic translation initiation factor eIF3。
13.	Brass, V., Moradpour, D.; Blum, H. E.(2006)。Molecular Virology of Hepatitis C virus (HCV)。
14.	Beeck, A. O. D.; Voisset, C.; Bartosch, B.; Ciczora, Y.; Cocquerel, L.; Keck, Z.; Foung, S.; Cosset, F. L.; Dubussion, J.(2004)。Characterization of functional hepatitis C virus envelope glycoproteins。
15.	Brohm, C.; Steinmann, E.; Ffriesland, M.; Lorenz, I. C.; Patel, A.; Penin, F. et al.(2009)。Characterization of determinants important for hepatitis C virus p7 function in morphogenesis using transcomplementation。
16.	Beran, R. K.; Lindenbach, B. D.; Pyle, A. M.(2009)。The NS4A protein of hepatitis C virus promotes RNA-coupled ATP hydrolysis by the NS3 helicase。
17.	Brenner, C.; Grimm, S.(2006)。The permeability transition pore complex in cancer celldeath。
18.	Bowie, A. G.; Fitzgerald, K. A.(2007)。RIG-I: triing to discriminate between self and nonself RNA。
19.	Bigger, C. B.; Brasky, K. M.; Lanford, R. E.(2001)。DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection。
20.	Choo, Q. L.; Kuo, G.; Weiner, A. J. et al.(2009)。Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome。
21.	Chen, S. L.; Morgan, T. R.(2006)。The natural history of hepatitis C virus (HCV) infection。
22.	Chevaliez, D.; Pawlotsky, J. M.(2007)。Hepatitis C virus:virology, diagnosis and management of antiviral therapy。
23.	Courouce, A. M.; Bouchardeau, F.; Chauveau, P. et al.(1995)。Hepatitis C (HCV) infection in hemodialysis patients: HCV-RNA and antiHCV antibodies (third-generation assays)。
24.	Chuang, W. C., Sarkodie, F., Brown, C. J. et al.(2007)。Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population。
25.	Codes, L.; Asselah, T.; Cazals, H. D. et al.(2007)。Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy。
26.	Clercq, E.(2004)。Antivirals and antiviral strategies。
27.	Deleersnyder, V.; Pillez, A.; Wychowski, C.; Blight, K.; Xu, J.; Hahn, Y. S. et al.(1997)。Formation of native hepatitis C virus glycoprotein complexes。
28.	Diviney, S.; Tuplin, A.; Struthers, M.; Armstrong, V.; Elliott, R.M.; Simmonds, P. et al.(2008)。A hepatitis C virus cis-acting replication element forms a long-range RNA-RNA interaction with upstream RNA sequences in NS5B。
29.	Davis, G. L., Albright, J. E., Cook, S. F.; Rosenberg, D. M.(2003)。Projecting future complications of chronic hepatitis C in the United States。
30.	Elazar, M.; Liu, P.; Rice, C. M.; Glenn, J. S.(2004)。An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association correct localization of replication complex proteins and HCV RNA replication。
31.	Friebe , P.; Boudet , J.; Simorre , J. P. ; Bartenschlager, R.(2005)。Kissing-loop interaction in the 3'end of the hepatitis C virus genome essential for RNA replication。
32.	Francesco, R.; Migliaccio, G.(2005)。Challenges and successes in developing new therapies for hepatitis C。
33.	Farci, P., Alter, H. J.; Wong , D. et al.(1991)。A long-term study of hepatitis C virus replication in non-A, non-B hepatitis。
34.	Fanning, L. J.(2002)。The Irish paradigm on the natural progression of hepatitis C virus infection: an investigation in a homogeneous patient population infected with HCV 1b。
35.	Ferri, C.; Civita, L.; Cirafisi, C. et al.(1992)。Peripheral neuropathyin mixed cryoglobulinemia: clinical and electrophysiologic investigations。
36.	Fischer, R.; Schmitt , M.; Bode, J. G.; Haussinger, D.(2007)。Expression of the peripheraltype benzodiazepine receptor and apoptosis induction in hepatic stellate cells。
37.	Galossi, A.; Guarisco, R.; Bellis, L.; Puoti, C.(2007)。Extrahepatic manifestations of chronic HCV infection。
38.	Griffin, S. D.; Beales, L. P.; Clarke, D. S.; et al.(2003)。The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine。
39.	Gale, M. Jr.; Foy, E. M.(2005)。Evasion of intracellular host defence by hepatitis C virus。
40.	Gastaminza, P.; Cheng, G.; Wieland, S.; Zhong, J.; Liao, W.; Chisari, F. V.(2008)。Cellular determinants of hepatitis C virus assembly maturation degradation and secretion。
41.	Gale, J. R.; Foy, E. M.(2005)。Evasion of intracellular host defence by hepatitis C virus。
42.	Hope, R. G.; Murphy, D. J.; Mclauchlan, J.(2002)。The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common fratures with plant oleosin proteins。
43.	Hofmann, W. P.; Zeuzem, S.; Sarrazin, C.(2005)。Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy。
44.	Hijikata, M.; Kato, N.; Ootsuyma, Y.; Nakagawa, M.; Shimotohno, K.(2000)。Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis。
45.	Hoofnagle, J. H.(2002)。Course and outcome of hepatitis C。
46.	Hadziyannis, S. J.; Sette, H. J.; Morgan, T. R. et al.(2004)。Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose。
47.	Jopling, C. L.; Norman, K. L.; Sarnow, P.(2006)。Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122。
48.	Johnson, R. J.; Gretch, D. R.; Yamabe, H. et al.(1993)。Membranoproliferative glomerulonephritis associated with hepatitis C virus infection。
49.	Joyce, M. A.; Walters, K. A.; Lamb, S. E.; Yeh, M. M.; Zhu, L. F.; Kneteman, J. S. et al.(2009)。HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice。
50.	Kobayashi, M.; Watanabe, K.; Ishigami, M. et al.(2002)。Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon。
51.	Klenerman, P.; Kim, A.(2007)。HCV-HIV coinfection:simple messages from a complex disease。
52.	Lindenbach, B. D.; Rice, C. M.(2005)。Unravelling hepatitis C virus replication from genome to function。
53.	Lai, C. K.; Jeng, K. S.; Machida, K.; Lai, M. M.(2008)。Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A。
54.	Lauer, G.; Walker, B. D.(2002)。Hepatitis C virus infection。
55.	Lee, C. M.; Hung, C. H.; Lu, S. N. et al.(2006)。Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan。
56.	Lee, C. M.; Hung, C. H.; Tung, W. C.; Wang, J. H.; Tung, H. D.; Chen, C. H. et al.(2006)。Hepatitis C virus genotypes in southern Taiwan:prevalence and clinical implications。
57.	Lin, H. H.; Kao, J. H.; Mizokami, M. et al.(1996)。Serotypes, genotypes and levels of hepatitis C viremia in pregnant women in Taiwan。
58.	Lin, W.; Kim, S. S.; Yeung, E.; Kamegaya, Y.; Blackard, J. T.; Kim, K. A. et al.(2006)。Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain。
59.	Loo, Y. M.; Owen, D. M.; Li, K.; Erickson, A. K.; Johnson, C. L.; Fish, P. M. et al.(2006)。Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection。
60.	Lee, S. D.; Yu, M. L.; Cheng, P. N. et al.(2005)。Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan。
61.	Lindsay, K. L.; Trepo, C.; Heintges, T. et al.(2001)。A randomized double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C。
62.	Mori, N.; Imamura, M.; Kawakami, Y. et al.(2009)。Randomized trial of high- dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy。
63.	Moradpour, D.; Brass, V.; Bieck, E. et al.(2004)。Membrane association of the RNADependent RNA polymerase is essential for hepatitis C virus RNA replication。
64.	Munoz, D. R. P.; Casado, J.; Paton, R. et al.(2008)。Mutations in E2-PePHD, NS5APKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses。
65.	Michael, A.; Joyce.; Lorne, D.; Tyrrell, J.(2010)。The cell biology of hepatitis c virus。
66.	Miyanari, Y.; Atsuzawa, K.; Usuda, N.; Watashi, K.; Hishiki, T.; Zayas, M. et al.(2007)。The lipid droplet is an important organelle for hepatitis C virus production。
67.	Murray, C. L.; Jones, C. T.; Tassello, J.; Rice, C. M.(2007)。Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus。
68.	Monga, H. K.; Rodriguez, M. C.; Breaux, K. et al.(2001)。Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection。
69.	Moucari, R.; Asselah, T.; Cazals, H. D. et al.(2008)。Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4 serum HCV RNA level and liver fibrosis。
70.	Misiani, R.; Bellavita, P.; Fenili, D. et al.(1992)。Hepatitis C virus infection in patients with essential mixed cryoglobulinemia。
71.	Meylan, E.; Curran, J.; Hofmann, K.; Moradpour, D.; Binder, M.; Bartenschlager, R. et al.(2005)。Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus。
72.	Mchutchison, J. G.; Gordon, S. C.; Schiff, E. R. et al.(1998)。Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C。
73.	Mangia, A.; Santoro, R.; Minerva, N. et al.(2005)。Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3。
74.	Mulhall, B. P.; Younossi, Z.(2005)。Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C。
75.	Nakai, K.; Okamoto, T.; Kimura, T.; Ishii, K.; Kim. C. K.; Tani, H. et al.(2006)。Oligomerization of hepatitis C virus core protein is crucial for interaction with the cytoplasmic domain of E1 envelope protein。
76.	Neyts, J.(2006)。Selecive inhibitors of hepatitis C virus replication。
77.	Otta, G. A.; Puglisi, J. D.(2004)。The pathway of HCV IRES-mediated translation initiation。
78.	Pileri, P.; Uematsu, Y.; Campagnoli, S. et al.(2003)。Binding of hepatitis C virus to CD81。
79.	Pavlovic, D.; Neville, D. C.; Argaud, O. et al.(2003)。The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkylchain iminosugar derivatives。
80.	Poynard, T.; Yuen, M. F.; Ratziu, V.; Lai, C. L.(2003)。Viral hepatitis C。
81.	Pawlotsky, J. M.; Roudot, T. F.; Simmonds, P. et al.(1995)。Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes。
82.	Papatheodoridis, G. V.; Manolakopoulos, S., Dusheiko, G.; Archimandritis, A. J.(2008)。Therapeutic strategies in the management of patients with chronic hepatitis B virus infection。
83.	Rustgi, V. K.(2007)。The epidemiology of hepatitis C infection in the United States。
84.	Song, Y.; Friebe, P.; Tzima, E.; Junemann, C.; Bartenschlager, R.; Niepmann, M.(2006)。The hepatitis C virus RNA 3’ -untranslated region strongly enhances translation directed by the internal ribosome entry site。
85.	Simmonds, P.(2004)。Genetic diversity and evolution of hepatitis C virus--15 years on。
86.	Sarrazin, C.; Herrmann, E.; Bruch, K.; Zeuzem, S.(2002)。Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analysis。
87.	Schregel, V.; Jacobi, S.; Penin, F.; Tautz, N.(2009)。Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3。
88.	Steinkuhler, C.; Urbani, A.; Tomei, L.; Biasiol, G.; Sardana, M.; Bianchi, E. et al.(1996)。Activity of purified hepatitis C virus protease NS3 on peptide substrates。
89.	Serag, H. B.; Mason, A. C.(1999)。Rising incidence of hepatocellular carcinoma in the United States。
90.	Saadoun, D.; Asselah, T.; Resche, R. M. et al.(2006)。Cryoglobulinemia is associated with steatosis and firbosis in chronic hepatitis C。
91.	Strader, D, B.; Wright, T.; Thomas, D. L.; Seeff, L. B.(2004)。American Association for the Study of Liver Disease Diagnosis management and treatment of hepatitis C。
92.	Timm, J.; Roggendorf, M.(2007)。Sequence diversity of hepatitis C virus:implication for immune control and therapy。
93.	Tan, S. L.; Katze, M. G.(2001)。How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A。
94.	Torres, P. M.; Cuevas, J. M.; Jimenez, H. N. et al.(2008)。Genetic variability in hepatitis C virus and its role in antiviral treatment response。
95.	Targett, P.; Boulant, S.; Mclauchlan, J.(2008)。Visualization of doublestranded RNA in cells supporting hepatitis C virus RNA replication。
96.	Templesmith, M., Gifford, S.; Stoove, M.(2004)。The lived experiences of men and women with hepatitis C : implications for support needs and health information。
97.	Ukai, K.; Ishigami, M.; Yoshioka, K. et al.(2006)。Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and。
98.	Webster, D. P.; Paul, K.; Jane, C.; Jeffery, K. J. M.(2009)。Development of novel Treatments for hepatits C。
99.	Wolk, B.; Buchele, B.; Moradpour, D.; Rice, C. M.(2008)。A dynamic view of hepatitis C virus replication complexes。
100.	Webster, D. P.; Klenerman, P.; Collier, J.; Jeffery, K. J. M.(2009)。Development of novel treatment for hepatitis C。
101.	Wang, J. T.; Wang, T. H.; Lin, J. T.; Lee, C. Z.; Sheu, J. C.; Chen, D. S.(1995)。Effect of hepatitis C antibody screening in blood donors on post-transfusion hepatitis in Taiwan。
102.	Wolk, B.; Sansonno, D.; Krausslich, H. G.; Dammacco, F.; Rice, C. M.; Blum, H.E. et al.(2000)。Subcellular localization stability and transcleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines。
103.	You, S.; Stump, D. D.; Branch, A. D.; Rice, C. M.(2004)。A cis-acting replication element in the sequence encoding the NS5B RNAdependent RNA polymerase is required for hepatitis C virus RNA replication。
104.	Yanagi, M.; Claire, M.; Emerson, S. U.; Purcell, R. H.; Bukh, J.(2002)。In vivo analysis of the 3'untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone。
105.	Yu, K. L.; Jang, S. I.; You, J. C.(2009)。Identification of in vivo interaction between hepatitis C virus core protein and 5'and 3' UTR RNA。
106.	Yi, M.; Ma, Y.; Yates, J.; Lemon, S. M.(2009)。Trans-complementation of an NS2 Defect in a late step in hepatitis C virus (HCV) particle assembly and maturation。
107.	Yu, M. L.; Dai, C. Y.; Huang, J. F. et al.(2007)。A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C。
108.	Zoulim, F.; Chevallier, M.; Maynard, M.; Trepo, C.(2003)。Clinical consequences of hepatitis C virus infection。
109.	Zucker, D. M.; Miller, B. W.(2001)。Assessment of side effects in patients with chronic hepatitis C receiving combination therapy。

推文
推薦
引用網址
引用嵌入語法
轉寄

top

:::

相關期刊
相關論文
相關專書
相關著作
熱門點閱

1.	2001~2015年臺灣肝癌發生率終生風險

無相關博士論文

無相關書籍

無相關著作

1.	從C型肝炎病毒感染細胞之凋亡談現行治療之免疫機轉

QR Code

臺灣人文及社會科學引文索引資料庫系統

詳目顯示

臺灣人文及社會科學引文索引資料庫